https://orcid.org/0000-0002-7719-9308
Figures
Abstract
Background
Vancomycin has been widely used in the last six decades to treat methicillin-resistant S. aureus (MRSA) and other resistant gram-positive infections. The risk of vancomycin toxicity increases with the utilization of higher doses while treating the resistant form of bacterial infections. Nephrotoxicity is one of the major complications reported to be a hinderance in the prognosis of vancomycin therapy.
Objectives
This hospital-based study aimed to highlight the influence of vancomycin on renal function with special emphasis on identifying the predictors and augmenting factors for nephrotoxicity.
Methodology
A cross-sectional, unicentric, hospital-based study was conducted at King Fahad Specialist Hospital (KFSH) in Qassim region in Saudi Arabia (KSA). It included 319 hospitalized patients who received vancomycin at intermittent doses (15 to 30 mg/kg IV per day) based on the diseased state. Data regarding vancomycin dose, frequency, duration and data of renal function tests and type of admission were analysed to evaluate their influence on the renal function using parameters such as blood urea, serum creatinine levels and creatinine clearance. One-way ANOVA and Spearman correlation test were used in the analysis of data.
Results
Both male and female patients treated with vancomycin had significantly (p<0.05) elevated blood urea and serum creatinine levels compared to baseline levels while creatinine clearance was non-significantly varied. Increasing age, increasing body weight, higher vancomycin dose and trough levels, increased vancomycin frequency and duration, critically ill patients and site of infection were factors associated with significant (p<0.05) increases in blood urea and serum creatinine levels with reduction in creatinine clearance.
Conclusion
Data suggested that vancomycin treatment reduced the renal function in patients and indicated its association with several predictors and confounding factors. The findings of the study might assist in identifying the patients under risk from the vancomycin-induced nephrotoxicity and in designing the preventive strategies to reduce such complications.
Citation: Altowayan WM, Mobark MA, ALharbi A, Alduhami AA, Rabbani SI (2023) The influence of vancomycin on renal functions, the predictors and associated factors for nephrotoxicity. PLoS ONE 18(4): e0284223. https://doi.org/10.1371/journal.pone.0284223
Editor: Lakshmi Kannan, Pikeville Medical Center, UNITED STATES
Received: January 22, 2023; Accepted: March 27, 2023; Published: April 17, 2023
Copyright: © 2023 Altowayan et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: All relevant data are within the paper.
Funding: Unfunded studies The authors received no specific funding for this work.
Competing interests: The authors have declared that no competing interests exist.
Introduction
Vancomycin is a glycopeptide antibiotic that has been widely used for over 65 years to treat methicillin-resistant S. aureus (MRSA) and other resistant gram-positive infections.
In published guidelines, a high dose of vancomycin has been recommended to overcome MRSA strains [1]. However, close monitoring and optimization of vancomycin doses is rather important as sub-dosing contributes to vancomycin resistance while higher extra-dose is associated with risk of toxicity [2]. Most of the therapeutic guidelines recommend monitoring of vancomycin based on the trough concentration [3]. For MRSA infection, the trough recommended concentration is 10 to 20 mg/L, and for severe infection, the recommended concentration is 15 to 20 mg/L [4]. Although vancomycin trough level monitoring is essential for follow-up of patients, other factors that influence vancomycin trough levels need to be considered, as significantly higher vancomycin trough level was seen among female patients and in critically ill patients, in addition to significant correlation with the site of infection [5].
Vancomycin is eliminated from the body primarily by the renal route via both glomerular filtration and active tubular secretion. So in a setting of normal creatinine clearance, vancomycin has a β-elimination half-life of 6–12 hours [6, 7].
The published data related to direct causal association between vancomycin and nephrotoxicity are still limited and further complicated with the presence of multiple confounding nephrotoxic factors, and there is a little evidence of nephrotoxicity with vancomycin used alone [8, 9]. However, vancomycin nephrotoxicity was reported to occur at doses above 4 g/day [10].
According to 2009 vancomycin consensus review, vancomycin-induced nephrotoxicity was defined as “a minimum of two increases in serum creatinine of at least 0.5 mg/dL or a 50% or greater increase in the serum creatinine from baseline after several days of vancomycin therapy” [11]. The reported incidence of vancomycin-associated acute kidney injury (VA-AKI) in hospitalized patients with eGFR > 30 ml/min was 11.7% and serum vancomycin levels of > 20 mg/L; hypotension and administration of iodinated contrast significantly increase this risk [12].
In this retrospective, hospital-based study we investigated the influence of vancomycin on the parameters of renal function within the context of vancomycin dose, frequency, duration and trough levels beside patients’ characteristics, site of infection and the disease status.
Material and methods
Study design
This study was a cross-sectional, unicentric, hospital-based study. It was conducted at KFSH in Qassim region in KSA from 1st April 2021 to 30th June 2022. It was approved by the Qassim Region Research Ethics Committee registered at the National Committee of Bio and Med. Ethics (NCBE), numbered: 1441–1064521.
Study participants
This study included 319 patients diagnosed with bacterial infections who received vancomycin at intermittent doses that varied according to body weight and disease severity, with doses ranging from 15 to 30 mg/kg IV per day. Patients known to have renal impairment and paediatric patients less than 10 years old were excluded from the study. The blood urea, serum creatinine and serum vancomycin trough level assays were run at the hospital central laboratory. For serum vancomycin trough level, the samples were drawn within 15 to 45 minutes before the administration of the fourth vancomycin dose. The creatinine clearance (CrCl) was calculated using Cockcroft-Gault equation [13].
Data collection
The patients’ data was obtained from KFSH records (laboratory and inpatients’ records). The data collection sheet was designed into three parts; the first part included the demographic characteristics of the patients: age, gender, weight and body mass index. The second part concerned types of patients’ admission (ICU versus non-ICU), the site of infections, and the laboratory results of renal function test: Blood urea, serum creatinine and creatinine clearance. The third part was concerned with vancomycin related data: dose, frequency, duration of treatment and the vancomycin trough level. The mean and standard deviation of the baseline values for renal function test and vancomycin trough level were obtained from the hospital laboratory data based on the stated baseline reference ranges for each test.
Statistical analysis
Statistical analysis of the results was done using the SPSS IBM 25 software. One-way ANOVA was used to determine the significance variation between treatment and baseline groups. Spearman correlation test was utilized to determine the association between the variables and serum trough level of vancomycin. The confidence interval of 95% (upper and lower) was computed for all the variables tested in the study. P<0.05 was considered to indicate the significance of the results.
Results
A. The demographic characters and the effect of vancomycin on the renal function in patients treated with vancomycin
The demographic data of 319 patients treated with vancomycin indicated that males (51.7%) were slightly more than females. Both male and female patients had significantly (P<0.05) elevated blood urea levels compared to baseline levels. The serum creatinine levels were also found to be elevated significantly (P<0.05) in both male and female patients but the creatinine clearance was non-significantly varied compared to baseline values. The trough level analysis indicated that female patients had significantly (P<0.05) higher levels compared to baseline value. In the age-group analysis, patients over 41 years old showed significantly (P<0.05) more vancomycin trough levels and the highest value (above 22 mg/L, P<0.01) was observed in patients older than 81 years. In the age-group, patients aged between 51 and 90 years were found to have significantly (P<0.01) higher blood urea levels compared to baseline. Further, the serum creatinine levels were found to be significantly (P<0.05) elevated in patients aged 10–20 years and 41–90 years when compared to baseline values. Besides, a significantly (P<0.05) lower creatinine clearance was observed in all patients aged above 61 years when comparison was done with baseline value Table 1.
B. Effect of vancomycin on renal functions in patients according to their body weight and body mass index
The analysis of vancomycin trough level according to body weight indicated that patients above 71 kgs have significantly (P<0.05) higher levels. Similarly, the patients with BMI greater than 29.1 showed significantly (P<0.05) elevated trough levels compared to baseline.
Further, the analysis of body weight data indicated that patients with weights above 71 kgs and those taking vancomycin had significantly (P<0.05) higher blood urea levels compared to baseline. The level of serum creatinine was found to be significantly (P<0.05) elevated in patients having body weight above 51 kgs compared to baseline. However, no significant difference was observed in the creatinine clearance among patients with different body weights.
The values obtained for body mass index suggested that patients taking vancomycin and having body mass index above 25.1–39.9 have significantly (P<0.05) higher blood urea levels compared to baseline. In patients with BMI above 40, the mean of blood urea (12.35 ± 4.52 mmol/L) is higher than the reference value, but the limited number (6 patients) in this group affects the statistical relationship. Serum creatinine levels were found to be significantly (P<0.05) increased in patients having body mass index above 18.1 compared to baseline. The analysis also indicated that the creatinine clearances were non-significantly affected in all the groups of body mass index patients, except those between 29.1 and 34.9 where it was significantly (P<0.05) low compared to baseline Table 2.
C. Effect of vancomycin on the renal functions according to dose, frequency and duration of treatment
Table 3 indicates the influence of vancomycin treatment regimen on the renal function. Patients administered vancomycin above 1250 mg had significantly (P<0.05) higher trough levels compared to baseline. Further, the patients receiving the drug thrice daily indicated elevated (P<0.05) trough levels. And patients administered vancomycin for 14 to 21 days were also found to have significantly (P<0.05) higher trough levels.
The doses of vancomycin such as 750 mg (P<0.05), 1250 mg (P<0.01) and 1500 mg (P<0.001) were found to significantly increase the blood urea levels compared to baseline. Further, two tested doses of vancomycin (1250 mg and 1500 mg) significantly (P<0.05) increased the serum creatinine levels and also reduced the creatinine clearance compared to baseline values.
Dose frequency of vancomycin suggests that when the drug was administered three times a day, the blood urea level was found to be significantly (P<0.05) increased compared to baseline. Similarly, this frequency of vancomycin dosing also significantly reduced (P<0.05) the creatinine clearance compared to baseline. The duration of treatment data reveal that vancomycin administration for 10–21 days is associated with significant (P<0.05) elevation of blood urea levels compared to baseline. And more than 10 days of vancomycin treatment significantly (P<0.05) reduced the creatinine clearance compared to control values.
D. Effect of vancomycin on renal function in different types of patients’ admission and site of infections
Analysis of the data suggested that patients admitted to ICU and CSICU have significantly (P<0.05) high vancomycin trough levels compared to baseline. Basically, the patients having infections of blood, abdomen, heart, sepsis, urinary tract and wounds indicated significantly (P<0.05) elevated vancomycin trough levels.
Depending on patients’ admission, the analysis of data also suggested that ICU (P<0.05) and CSICU (P<0.01) patients receiving vancomycin have significantly (P<0.05) higher blood urea levels. These admissions also had elevated serum creatinine levels [ICU (P<0.05) and CSICU–(P<0.01)] when compared with baseline values. The creatinine clearance was found to be significantly reduced in patients admitted to CCU (P<0.05), ICU (P<0.05) and CSICU (P<0.001) wards.
Influence of site of infection on kidney function suggested that infection of blood, heart, sepsis risk, urinary tract and lungs with vancomycin treatment had significantly (P<0.05) higher blood urea levels compared to baseline. Vancomycin treatment in patients diagnosed with infection of abdomen, heart, sepsis risk, urinary tract, wound and lungs showed significantly (P<0.05) higher serum creatinine levels. However, the creatinine clearance was found to be significantly (P<0.05) low only in patients indicated with heart and wound infections Table 4.
E. Correlation summary between the variables and renal functions after treatment with vancomycin
The comparative analysis between groups indicated that age (Rho = 0.342), duration of treatment (Rho = 0.273), patients’ admission (Rho = 0.321) and site of infection (Rho = 0.406) have significantly (P<0.05) higher vancomycin trough levels. Further, the correlation analysis done to determine the association between the confounding factor and outcome suggested that age, dose, frequency of dosing, patient’s admission and site of infection have significantly (P<0.05) influenced the elevated blood urea levels in patients receiving the vancomycin. The relationship was found to be more (Rho = 0.448) for the site of infection. Body weight, patient’s admission and site of infection were found to have a significant (P<0.05) role in the elevated serum creatinine levels. On the other hand, body mass index, dose and patient’s admission significantly (P<0.05) influenced the lower creatinine clearance in patients receiving the vancomycin treatment. The relationship was observed to be more significant (Rho = 0.385) between the increasing dose of vancomycin and low creatinine clearance Table 5.
Discussion
Although Vancomycin-associated nephrotoxicity has been faced with initial doubts as multiple other confounding risk factors may exist, more than one study reported an increased risk of nephrotoxicity with higher doses of vancomycin [1, 10, 14]. In this cross-sectional, unicentric, hospital-based study that was conducted at KFSH among 319 patients treated with vancomycin, the findings showed that both male and female patients treated with vancomycin had significant (P<0.05) elevated blood urea and serum creatinine levels compared to baseline levels. In 2013, a systematic review and meta-analysis study found that the collective literature reports a relationship between vancomycin exposure and nephrotoxicity and the causal association is more expected with increased vancomycin trough level concentration and the duration of therapy [15].
In this current study, we calculated the CrCl using Cockcroft-Gault formula and the findings in both male and female showed non-significant variation compared to baseline values. However, the effect of variation in body weight among the study participants should be considered. When using Cockcroft-Gault equation, overestimation of CrCl is expected especially for obese patients as their TBW includes a disproportionately greater amount of non-muscle tissue as compared to the Cockcroft and Gault study population [16]. Interestingly, a meta-analysis of 13 studies done by Wilhelm and Kale-Pradhan reported that “using TBW in Cockcroft-Gault equation overestimates measured CrCl and using IBW underestimates measured CrCl, while using an adjusted body weight (ABW) with a correction factor of either 0.3 or 0.4 to adjust for the difference between TBW and IBW produced a slight overestimation” [17]. In another study, Aimo Harmoinen and his colleagues reported that GFR values calculated by the Cockcroft-Gault formula were ∼10% higher than the plasma 51Cr-EDTA clearance values [18]. Shoker and his colleagues suggested that “normalization for body surface area in the original Cockcroft-Gault formula demonstrated more accuracy to estimate creatinine clearance” [19].
This study found a significant increase in vancomycin trough levels compared to baseline in patients above 41 years and, linked to that, significantly higher blood urea levels compared to baseline were found in patients aged between 51 and 90 years. Further, the serum creatinine levels were found to be significantly elevated in patients 41–90 years when compared to baseline values. In addition to that, a significant (P<0.05) lower creatinine clearance in all patients aged above 61 years is seen.
As reported previously, the risk of vancomycin-associated nephrotoxicity was higher among elderly patients compared to younger patients [20]. Moreover, the risk of vancomycin-associated nephrotoxicity increases to 3-fold with vancomycin trough concentrations of >15 mg/ml [21].
In the present study the analysis of vancomycin trough level indicated significantly higher levels in patients who weighed over 71 kgs and BMI greater than 29.1. Similarly, higher blood urea levels compared to baseline were found in patients who weighed more than 71 kgs while serum creatinine was found to be significantly elevated in patients weighing over 51 kgs. Regarding BMI, significantly higher blood urea levels compared to baseline were found in patients having body mass index above 25.1–39.9. The analysis also indicated that the creatinine clearances were non-significantly affected in all the groups of body mass index patients, except 29.1–34.9 where it was significantly (P<0.05) low compared to baseline. These findings also point to the effect of weight on calculation of creatinine clearance using Cockcroft-Gault formula. The increase in body weight increases the drug exposure based on dosing calculations and volume of distribution estimation. In line with these findings, in a review study from 2016 they reported obesity as a risk factor for vancomycin-associated nephrotoxicity [22]. More than one study also reported obesity as a risk for vancomycin-associated nephrotoxicity [23–25]. In contradiction to these findings, a study done in 2015 for obesity as a factor in vancomycin-associated nephrotoxicity concluded that “no difference in nephrotoxicity was observed between lean and obese patients treated with vancomycin at our institution” [9].
This study indicated that vancomycin dose above 1250 mg, frequency of thrice daily and duration of 14 to 21 days had significantly higher trough levels compared to baseline. Linear to these, the doses of vancomycin such as 750 mg, 1250 mg and 1500 mg, and vancomycin administration three times a day significantly increased the blood urea and serum creatinine levels and reduced the creatinine clearance compared to baseline values. The vancomycin administration for 10–21 days is associated with significant elevation of blood urea levels and reduction in creatinine clearance. The increase in dose, frequency and duration of vancomycin logically increases the drug exposure reflected as increased vancomycin trough levels and hastens the mechanism by which vancomycin affects renal function. The risk of vancomycin-associated nephrotoxicity with the use of large doses was reported in many studies [10, 26–29]. In another study, Contreiras and his colleagues concluded that “patients receiving vancomycin for more than 7 days had an increased likelihood of experiencing nephrotoxicity” [30].
The current study highlighted that ICU and CSICU admitted patients have significantly high vancomycin trough levels compared to baseline together with significantly higher blood urea, higher serum creatinine levels and significantly reduced creatinine clearance. Besides that, the patients’ having infections of blood, abdomen, heart, sepsis, urinary tract and wound indicated significantly elevated vancomycin trough levels and significant elevation of both blood urea and serum creatinine. The critically ill patients are hemodynamically unstable and kidney function is already compromised with the underlying disease state so they are at greater risk of renal deterioration following use of medications even with minimal risk of injury to the kidneys. Moreover, critically ill patients receive multiple medications which further increases the risk of nephrotoxicity. Vancomycin dose adjustment, close monitoring and observation of renal function is of utmost importance in critically ill patients. Malacarne and colleagues reported a significant nephrotoxic event occurred in critically ill patients with septic shock due to concurrent administration of vancomycin and aminoglycosides [31]. In critically ill patients with cardiac surgery, vancomycin was reported to have an association with deterioration of renal function [32]. Most of the reported vancomycin-associated nephrotoxicity occurs in critically ill patients [22, 33–35].
Conclusion
This cross-sectional, unicentric, hospital-based study at KFSH found that both male and female patients treated with vancomycin had significantly elevated blood urea and serum creatinine levels compared to baseline levels while CrCl calculated by Cockcroft-Gault formula showed non-significant variation compared to baseline values. Increased age, increase in weight, higher vancomycin dose, increased frequency, prolonged duration of treatment, critically ill patients and site of infection have significantly higher vancomycin trough levels and significantly elevated blood urea and serum creatinine levels compared to baseline with significantly influenced lower creatinine clearance. These factors can be evaluated and regarded as pre-treatment predictors of vancomycin-associated nephrotoxicity, especially in critically ill patients.
Limitations of the study
- The primary limitation of this study is the retrospective design with a limited number of patients.
- The inherent factors and the state of the infection may have an impact on the renal function and represent confounders for accurate judgment regarding vancomycin-associated nephrotoxicity.
- History of long term use of medications is not addressed and certain medications have a negative impact on renal function.
- Calculation of CrCl using Cockcroft-Gault formula as measured creatinine clearance would yield more accurate results.
Acknowledgments
The researchers would like to thank the Deanship of Scientific Research, Qassim University for funding the publication of this project.
References
- 1. Jeffres MN, Isakow W, Doherty JA, Micek ST, Kollef MH. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia. Clinical therapeutics. 2007 Jun 1;29(6):1107–15. pmid:17692725
- 2. Ingram PR, Lye DC, Tambyah PA, Goh WP, Tam VH, Fisher DA. Risk factors for nephrotoxicity associated with continuous vancomycin infusion in outpatient parenteral antibiotic therapy. Journal of antimicrobial chemotherapy. 2008 Jul 1;62(1):168–71. pmid:18334494
- 3. Rybak MJ, Lomaestro BM, Rotscahfer JC, Moellering RC Jr, Craig WA, Billeter M, et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clinical infectious diseases. 2009 Aug 1;49(3):325–7. pmid:19569969
- 4. Rybak MJ, Le J, Lodise TP, Levine DP, Bradley JS, Liu C, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Clinical Infectious Diseases. 2020 Sep 15;71(6):1361–4. pmid:32658968
- 5. Altowayan WM, Mobark MA, Alharbi AS, Alduhami AA, Rabbani SI. Factors influencing the vancomycin trough level in patients admitted at King Fahad Specialist Hospital, Qassim, KSA. European Review for Medical and Pharmacological Sciences. 2022 Jan 1;26(13):4840–5. pmid:35856376
- 6. Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clinical Infectious Diseases. 2006 Jan 1;42(Supplement_1):S35–9. pmid:16323118
- 7. Vora S. Acute renal failure due to vancomycin toxicity in the setting of unmonitored vancomycin infusion. InBaylor University Medical Center Proceedings 2016 Oct 1 (Vol. 29, No. 4, pp. 412–413). pmid:27695180
- 8.
Patel S, Preuss CV, Bernice F. Vancomycin. 2023 Jan 14. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–.
- 9. Davies SW, Efird JT, Guidry CA, Dietch ZC, Willis RN, Shah PM, et al. Vancomycin-associated nephrotoxicity: the obesity factor. Surgical infections. 2015 Dec 1;16(6):684–93. pmid:26324996
- 10. Lodise TP, Lomaestro B, Graves J, Drusano GL. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrobial agents and chemotherapy. 2008 Apr;52(4):1330–6. pmid:18227177
- 11. Martin JH, Norris R, Barras M, Roberts J, Morris R, Doogue M, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society Of Infectious Diseases Pharmacists. The Clinical biochemist Reviews. 2010 Feb;31(1): 21–4. pmid:20179794; PMCID: PMC2826264.
- 12. Yalamarti T, Zonoozi S, Adu Ntoso K. Alborzi P. Incidence and risk factors of vancomycin-associated acute kidney injury in a single center: Retrospective study. J Clini Nephrol. 2021; 5: 010–016.
- 13. Cockcroft DW, Gault H. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41. pmid:1244564
- 14. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Archives of internal medicine. 2006 Oct 23;166(19):2138–44. pmid:17060545
- 15. van Hal SJ, Paterson DL, Lodise TP. Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrobial agents and chemotherapy. 2013 Feb;57(2):734–44. pmid:23165462
- 16. Demirovic JA, Pai AB, Pai MP. Estimation of creatinine clearance in morbidly obese patients. American Journal of Health-System Pharmacy. 2009 Apr 1;66(7):642–8. pmid:19299371
- 17. Wilhelm SM, Kale‐Pradhan PB. Estimating creatinine clearance: a meta‐analysis. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2011 Jul;31(7):658–64. pmid:21923452
- 18. Harmoinen A, Lehtimaki T, Korpela M, Turjanmaa V, Saha H. Diagnostic accuracies of plasma creatinine, cystatin C, and glomerular filtration rate calculated by the Cockcroft–Gault and Levey (MDRD) formulas. Clinical Chemistry. 2003 Jul 1;49(7):1223–5. pmid:12816933
- 19. Shoker A, Hossain MA, Koru-Sengul T, Raju DL, Cockcroft D. Performance of creatinine clearance equations on the original Cockcroft-Gault population. Clinical nephrology. 2006 Aug 1;66(2):89–97. pmid:16939064
- 20. Vance-Bryan K, Rotschafer JC, Gilliland SS, Rodvold KA, Fitzgerald CM, Guay DR. A comparative assessment of vancomycin-associated nephrotoxicity in the young versus the elderly hospitalized patient. Journal of Antimicrobial Chemotherapy. 1994 Apr 1;33(4):811–21. pmid:8056700
- 21. Bosso JA, Nappi J, Rudisill C, Wellein M, Bookstaver PB, Swindler J, et al. Relationship between vancomycin trough concentrations and nephrotoxicity: a prospective multicenter trial. Antimicrobial agents and chemotherapy. 2011 Dec;55(12):5475–9. pmid:21947388
- 22. Bamgbola O. Review of vancomycin-induced renal toxicity: an update. Therapeutic advances in endocrinology and metabolism. 2016 Jun;7(3):136–47. pmid:27293542
- 23. Choi Y. C. et al., “Intravenous Vancomycin Associated With the Development of Nephrotoxicity in Patients With Class III Obesity,” Ann. Pharmacother., vol. 51, no. 11, pp. 937–944, Nov. 2017. pmid:28709394
- 24. Wolfe A, Bowling J, Short MR, Mateyoke G, Berger SC. Assessing nephrotoxicity associated with different vancomycin dosing modalities in obese patients at a community hospital. Hospital Pharmacy. 2022 Aug;57(4):532–9. pmid:35898248
- 25. Miyai T, Imai S, Kashiwagi H, Sato Y, Kadomura S, Yoshida K, et al. A risk prediction flowchart of vancomycin-induced acute kidney injury to use when starting vancomycin administration: a multicenter retrospective study. Antibiotics. 2020 Dec 18;9(12):920. pmid:33352848
- 26. Pritchard L, Baker C, Leggett J, Sehdev P, Brown A, Bayley KB. Increasing vancomycin serum trough concentrations and incidence of nephrotoxicity. The American journal of medicine. 2010 Dec 1;123(12):1143–9. pmid:21183005
- 27. Davies SW, Guidry CA, Petroze RT, Hranjec T, Sawyer RG. Vancomycin and nephrotoxicity; just another myth?. The journal of trauma and acute care surgery. 2013 Nov;75(5):830. pmid:24158202
- 28. Burgess LD, Drew RH. Comparison of the incidence of vancomycin‐induced nephrotoxicity in hospitalized patients with and without concomitant piperacillin‐tazobactam. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2014 Jul;34(7):670–6. pmid:24855041
- 29. Hanrahan TP, Kotapati C, Roberts MJ, Rowland J, Lipman J, Roberts JA, et al. Factors associated with vancomycin nephrotoxicity in the critically ill. Anaesthesia and intensive care. 2015 Sep;43(5):594–9. pmid:26310409
- 30. Contreiras C, Legal M, Lau TT, Thalakada R, Shalansky S, Ensom MH. Identification of risk factors for nephrotoxicity in patients receiving extended-duration, high-trough vancomycin therapy. The Canadian journal of hospital pharmacy. 2014 Mar;67(2):126. pmid:24799722
- 31. Malacarne P, Bergamasco S, Donadio C. Nephrotoxicity due to combination antibiotic therapy with vancomycin and aminoglycosides in septic critically ill patients. Chemotherapy. 2006;52(4):178–84. pmid:16691027
- 32. Hutschala D, Kinstner C, Skhirdladze K, Thalhammer F, Müller M, Tschernko E. Influence of Vancomycin on Renal Function in Critically Ill Patients after Cardiac Surgery: Continuous versusIntermittent Infusion. The Journal of the American Society of Anesthesiologists. 2009 Aug 1;111(2):356–65. pmid:19602966
- 33. Meaney CJ, Hynicka LM, Tsoukleris MG. Vancomycin‐associated nephrotoxicity in adult medicine patients: incidence, outcomes, and risk factors. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2014 Jul;34(7):653–61. pmid:24700598
- 34. Hanrahan TP, Harlow G, Hutchinson J, Dulhunty JM, Lipman J, Whitehouse T, et al. Vancomycin-associated nephrotoxicity in the critically ill: a retrospective multivariate regression analysis. Critical care medicine. 2014 Dec 1;42(12):2527–36. pmid:25083977
- 35. Feiten HDS, Okumura LM, Martinbiancho JK, Andreolio C, da Rocha TS, Antonacci Carvalho PR, et al. Vancomycin-associated Nephrotoxicity and Risk Factors in Critically Ill Children Without Preexisting Renal Injury. Pediatr Infect Dis J. 2019 Sep;38(9):934–938. pmid:31232892